相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Modelling of the relationship between infliximab exposure, faecal calprotectin and endoscopic remission in patients with Crohn's disease
Erwin Dreesen et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2021)
Dose optimisation for Loss of Response to Vedolizumab - Pharmacokinetics and Immune Mechanisms
Bella Ungar et al.
JOURNAL OF CROHNS & COLITIS (2021)
Vedolizumab treatment persistence and safety in a 2-year data analysis of an extended access programme
Silvio Danese et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2021)
Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis
William J. Sandborn et al.
GASTROENTEROLOGY (2020)
Influence of Drug Exposure on Vedolizumab-Induced Endoscopic Remission in Anti-Tumour Necrosis Factor [TNF] Naive and Anti-TNF Exposed IBD Patients
Bram Verstockt et al.
JOURNAL OF CROHNS & COLITIS (2020)
Vedolizumab Efficacy, Safety, and Pharmacokinetics With Reduced Frequency of Dosing From Every 4 Weeks to Every 8 Weeks in Patients With Crohn's Disease or Ulcerative Colitis
Severine Vermeire et al.
JOURNAL OF CROHNS & COLITIS (2020)
Comparison of the ELISA and ECL Assay for Vedolizumab Anti-drug Antibodies: Assessing the Impact on Pharmacokinetics and Safety Outcomes of the Phase 3 GEMINI Trials
Timothy Wyant et al.
AAPS JOURNAL (2020)
Circulating exosomes express α4β7 integrin and compete with CD4+T cells for the binding to Vedolizumab
Rossana Domenis et al.
PLOS ONE (2020)
Loss of Response to Vedolizumab and Ability of Dose Intensification to Restore Response in Patients With Crohn's Disease or Ulcerative Colitis: A Systematic Review and Meta-analysis
Laurent Peyrin-Biroulet et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2019)
Vedolizumab Concentrations Are Associated with Long-Term Endoscopic Remission in Patients with Inflammatory Bowel Diseases
Andres J. Yarur et al.
DIGESTIVE DISEASES AND SCIENCES (2019)
Early vedolizumab trough levels predict combined endoscopic and clinical remission in inflammatory bowel disease
Jurij Hanzel et al.
UNITED EUROPEAN GASTROENTEROLOGY JOURNAL (2019)
Vedolizumab Induces Endoscopic and Histologic Remission in Patients With Crohn's Disease
Mark Lowenberg et al.
GASTROENTEROLOGY (2019)
Endoscopic, Radiologic, and Histologic Healing With Vedolizumab in Patients With Active Crohn's Disease
Silvio Danese et al.
GASTROENTEROLOGY (2019)
Vedolizumab is associated with changes in innate rather than adaptive immunity in patients with inflammatory bowel disease
Sebastian Zeissig et al.
GUT (2019)
Evidence to Support Monitoring of Vedolizumab Trough Concentrations in Patients With Inflammatory Bowel Diseases
Erwin Dreesen et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2018)
Exposure-efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's Disease
Maria Rosario et al.
JOURNAL OF CROHNS & COLITIS (2017)
The Real-World Effectiveness and Safety of Vedolizumab for Moderate-Severe Crohn's Disease: Results From the US VICTORY Consortium
Parambir S. Dulai et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2016)
An Overview of the Mechanism of Action of the Monoclonal Antibody Vedolizumab
Tim Wyant et al.
JOURNAL OF CROHNS & COLITIS (2016)
Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease
M. Rosario et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2015)
Population pharmacokinetics of infliximab in patients with inflammatory bowel disease: potential implications for dosing in clinical practice
D. J. Buurman et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2015)
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
L. Peyrin-Biroulet et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2015)
Loss of Infliximab Into Feces Is Associated With Lack of Response to Therapy in Patients With Severe Ulcerative Colitis
Johannan F. Brandse et al.
GASTROENTEROLOGY (2015)
Effects of Vedolizumab Induction Therapy for Patients With Crohn's Disease in Whom Tumor Necrosis Factor Antagonist Treatment Failed
Bruce E. Sands et al.
GASTROENTEROLOGY (2014)
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
Brian G. Feagan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
William J. Sandborn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Antibodies to constant domains of therapeutic monoclonal antibodies: Anti-hinge antibodies in immunogenicity testing
Theo Rispens et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2012)
Measurement of serum levels of natalizumab, an immunoglobulin G4 therapeutic monoclonal antibody
Theo Rispens et al.
ANALYTICAL BIOCHEMISTRY (2011)
Pharmacokinetic Properties of Infliximab in Children and Adults with Crohn's Disease: A Retrospective Analysis of Data from 2 Phase III Clinical Trials
Adedigbo A. Fasanmade et al.
CLINICAL THERAPEUTICS (2011)
Importance of Shrinkage in Empirical Bayes Estimates for Diagnostics: Problems and Solutions
Radojka M. Savic et al.
AAPS JOURNAL (2009)
Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis
Adedigbo A. Fasanmade et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis
GJ Wolbink et al.
ARTHRITIS AND RHEUMATISM (2006)
Quantification of lean bodyweight
S Janmahasatian et al.
CLINICAL PHARMACOKINETICS (2005)
Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD
M Daperno et al.
GASTROINTESTINAL ENDOSCOPY (2004)
分享论文
